CL2020003209A1 - Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas - Google Patents

Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas

Info

Publication number
CL2020003209A1
CL2020003209A1 CL2020003209A CL2020003209A CL2020003209A1 CL 2020003209 A1 CL2020003209 A1 CL 2020003209A1 CL 2020003209 A CL2020003209 A CL 2020003209A CL 2020003209 A CL2020003209 A CL 2020003209A CL 2020003209 A1 CL2020003209 A1 CL 2020003209A1
Authority
CL
Chile
Prior art keywords
composition
prevention
treatment
amino acids
liver diseases
Prior art date
Application number
CL2020003209A
Other languages
English (en)
Inventor
Paolo Luca Maria Giorgetti
Original Assignee
Professional Dietetics Int S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics Int S R L filed Critical Professional Dietetics Int S R L
Publication of CL2020003209A1 publication Critical patent/CL2020003209A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición para su uso en la prevención y/o tratamiento de una enfermedad hepática en un mamífero, la composición comprende un agente activo, dicho agente activo contiene los aminoácidos leucina, isoleucina, valina, treonina, lisina y los ácidos carboxílicos ácido cítrico, ácido succínico, ácido málico.
CL2020003209A 2018-06-27 2020-12-10 Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas CL2020003209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000006725A IT201800006725A1 (it) 2018-06-27 2018-06-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche

Publications (1)

Publication Number Publication Date
CL2020003209A1 true CL2020003209A1 (es) 2021-06-04

Family

ID=63491976

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003209A CL2020003209A1 (es) 2018-06-27 2020-12-10 Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas

Country Status (23)

Country Link
US (1) US12239622B2 (es)
EP (1) EP3586837B1 (es)
JP (1) JP7347744B2 (es)
KR (1) KR102769832B1 (es)
CN (1) CN112334129B (es)
AU (1) AU2019293293B2 (es)
BR (1) BR112020026431A2 (es)
CA (1) CA3104839A1 (es)
CL (1) CL2020003209A1 (es)
CY (1) CY1124030T1 (es)
DK (1) DK3586837T3 (es)
EA (1) EA202092749A1 (es)
ES (1) ES2858355T3 (es)
IT (1) IT201800006725A1 (es)
LT (1) LT3586837T (es)
MX (1) MX2020013471A (es)
MY (1) MY201355A (es)
PH (1) PH12020552254A1 (es)
PL (1) PL3586837T3 (es)
RS (1) RS61613B1 (es)
SG (1) SG11202012297XA (es)
WO (1) WO2020003013A1 (es)
ZA (1) ZA202007834B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
IT202000000454A1 (it) * 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
WO2022266480A1 (en) * 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof
IT202300009351A1 (it) * 2023-05-10 2024-11-10 Professional Dietetics Spa Composizioni comprendenti acido ialuronico, aminoacidi e intermedi del ciclo di krebs utili per aumentare l'espressione genica della matrice extracellulare

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537969B1 (en) * 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
ITTO20010804A1 (it) 2001-08-08 2003-02-08 Professional Dietetics Srl Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
US6620850B2 (en) 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
WO2007049818A1 (ja) * 2005-10-27 2007-05-03 Ajinomoto Co., Inc. 抗脂肪肝、抗肥満及び抗高脂血症用組成物
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
JP2007161642A (ja) 2005-12-14 2007-06-28 Kyowa Hakko Kogyo Co Ltd アルコール性肝障害抑制剤
WO2012111790A1 (ja) 2011-02-17 2012-08-23 味の素株式会社 化学療法剤の抗腫瘍活性増強剤
WO2012147901A1 (ja) 2011-04-28 2012-11-01 味の素株式会社 抗癌剤副作用改善用組成物
US20130084378A1 (en) * 2011-09-30 2013-04-04 Daesang Corporation Amino acid seasoning compositions comprising l-glutamic acid and l-lysine
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2013188874A1 (en) 2012-06-15 2013-12-19 Gencia Corporation Methods of mitigating side effects of radiation exposure and chemotherapy
CN102772407B (zh) 2012-08-01 2014-09-17 岳茂兴 一种促进神经损伤修复的药物组合物及其应用
US9597367B2 (en) * 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
EP3231437B1 (en) 2014-12-09 2020-02-05 Nihon Sizen Hakkoh Co., Ltd. Aging inhibitor
MX357998B (es) 2015-03-20 2018-07-11 Antonio Hernandez Miramontes Jorge Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
EP3294281A4 (en) * 2015-05-11 2019-01-23 Newcastle Innovation Limited AMINOSÄURESUPPLMENTIERUNG
MY187022A (en) * 2015-05-14 2021-08-26 Professional Dietetics Spa Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
WO2017020121A1 (en) 2015-07-31 2017-02-09 Val-Chum, Limited Partnership Glycerol-3-phosphate phosphatase activators
JP7366540B2 (ja) 2015-11-27 2023-10-23 ダブルグッド アクチエボラグ メタボリックシンドローム治療用栄養補助食品および食品組成物
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
EP3691628A1 (en) 2017-10-02 2020-08-12 University of Florida Research Foundation, Incorporated Materials and methods for inhibiting tumor growth
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000454A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
WO2022266480A1 (en) 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof

Also Published As

Publication number Publication date
US12239622B2 (en) 2025-03-04
SG11202012297XA (en) 2021-01-28
US20210260011A1 (en) 2021-08-26
CN112334129B (zh) 2025-01-03
JP7347744B2 (ja) 2023-09-20
MX2020013471A (es) 2021-02-18
CA3104839A1 (en) 2020-01-02
RS61613B1 (sr) 2021-04-29
EA202092749A1 (ru) 2021-06-23
KR102769832B1 (ko) 2025-02-17
DK3586837T3 (da) 2021-03-01
PH12020552254A1 (en) 2021-08-16
IT201800006725A1 (it) 2019-12-27
WO2020003013A1 (en) 2020-01-02
KR20210025611A (ko) 2021-03-09
CY1124030T1 (el) 2022-05-27
MY201355A (en) 2024-02-20
BR112020026431A2 (pt) 2021-03-30
ES2858355T3 (es) 2021-09-30
AU2019293293A1 (en) 2021-01-14
EP3586837A1 (en) 2020-01-01
CN112334129A (zh) 2021-02-05
ZA202007834B (en) 2021-10-27
JP2021529731A (ja) 2021-11-04
NZ771034A (en) 2025-09-26
AU2019293293B2 (en) 2024-12-12
LT3586837T (lt) 2021-05-10
EP3586837B1 (en) 2020-12-23
PL3586837T3 (pl) 2021-09-13

Similar Documents

Publication Publication Date Title
CL2020003209A1 (es) Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas
MX2022010774A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2021002131A1 (es) Uso de composiciones con aminoácidos para el tratamiento de lesiones del sistema nervioso central.
CL2022001779A1 (es) Composiciones que comprenden aminoácidos para la prevención y/o el tratamiento del cáncer
CL2020002252A1 (es) Formulación oftálmica.
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
PH12020500189A1 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
ZA201901370B (en) Formulations for oral administration of active agents
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
AR109798A1 (es) Composición para el tratamiento capilar
MX2019000849A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
BR112017016205A2 (pt) thymosin alpha 1 para uso no tratamento de fibrose cística
EP4566668A3 (en) Neurotoxins for use in minimizing scarring
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
NZ728962A (en) Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.
TH2001007315A (th) องค์ประกอบที่ประกอบรวมด้วยกรดอะมิโนสำหรับใช้ในการป้องกันและการรักษาโรคตับ
AR111668A1 (es) Composición antiséptica de una asociación de clorhexidina y de yodo